Attorney Docket No.: 6202.210-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Behrens et al

Application No.: To Be Assigned

Group Art Unit: To be assigned

Filed: September 9, 2003

Examiner: To be assigned

For: Glucagon Antagonists/Inverse Agonists

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/996,025 filed on November 16, 2001.

The references are as follows:

1. WO 00/39088

Attorney Docket No. 6202.210 -US Express Mail Label No. EV 246876620 US

- 2. WO 94/14426
- WO 98/04528
- WO 98/21957
- 5. WO 98/22108
- WO 98/22109
- 7. WO 99/01423
- 8. WO 97/16442
- 9. WO 98/24780
- 10. WO 98/24782
- 11. WO 99/24404
- 12. WO 99/32448
- 13. US 5,880,139
- 14. US 5,776,954
- 15. US 4.359.474
- 16. US 4,374,130
- 17. US 5,837,719
- 18. C.L. Brand et al., "Immunoneutralization of endogenous glucagons with monoclonal glucagons antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats" Diabetologia Vol. 37 pgs. 985-993 (1994)
- 19. C.L. Brand et al., [535] Diabetes 43, [suppl 1], 172A (1994)
- C. L. Brand et al., Am. J. Physiol. 269, E469-E477 (1995)
- 21. C.L. Brand et al [492] Diabetes 44 [suppl 1], 134A (1995)
- 22. C.L. Brand et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits"., Diabetes Vol. 45., pages. 1076-1083 (1996)
- 23. L.J.Jelinek et al., "Expression Cloning and Signaling Properties of the Rat Glucagon Receptor" Science Vol. 259, pages, 1614-1616 (1993)
- 24. C.G. Unson et al., "Biological Activities of des-His1 [Glu9]Glucagon Amide, a Glucagon Antagonist¹ " Peptides, Vol.10 pages 1171-1177 (1998)
- 25. Post et al., "Mechanism of action of des-His1-[Glu9]glucagons amide, a peptide antagonist of the glucagons receptor sytem" Proc. Natl. Acad. Sci Vol. 90 pages 1662-1666 (1993)
- 26. Azizeh et al., "[des His1, des Phe6, Glu9]GLUCAGON AMIDE: A NEWLY DESIGNED "PURE" GLUCAGON ANTAGONIST", Bioorganic & Med Chem Ltr. Vol. 5, No. 16, pages, 1849-1852 (1995)
- 27. Unson et al., "Multiple-site Replacement Analogs of Glucagon" The Journal of Biological Chemistry Vol. 17, Issue of April 29, pages, 12548-12551 (1994)
- 28. J.L. Collins et al., "CP-99, 711: A NON-PEPTIDE GLUCAGON RECEPTOR ANTAGONIST" Bioorganic & Med. Chem. Ltr. Vol. 2, No. 9 pages. 915-918 (1992)
- 29. P. Madsen et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists" J. Med. Chem Vol. 41, pages, 5150-5157 (1998)
- 30. WO 00/69810

Attorney Docket No. 6202.210 -US Express Mail Label No. EV 246876620 US

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: September 9, 2003

Richard W. Bork, Reg. No. 36,459 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401 (212) 867-0123

23650 PATENT TRADEMARK OFFICE

						si	neet 1 of 4	
FORM PTO-1449 U.S. DEPARTMENT OF COMMER (Rev. 2-32) PATENT AND TRADEMARK OFFI			Atty. Docket No. 6202.210-US Serial No. To Be Assigned			d		
	INFORMATION DISCLO STATEMENT BY APPLI		Applicant Behrens et al					
	(Use several sheets if neces	sary)	Filing Date September 9	Filling Date September 9, 2003 Group T be assigned				
		U.S. PAT	ENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	5,880,139	03/09/99	L.L. Chang	514	326	11/1	7/97	
	5,776,954	07/07/98	de Laszlo et al	514	340	10/30/96		
	4,359,474	11/16/82	Anderson et al	424	273	11/28/80		
	4,374,130	02/15/83	Barcza	424	184	02/15/83		
	5,837,719	11/17/98	de Laszlo et al	514	343	08/0	8/96	
		FOREIGN P	PATENT DOCUMENTS					
	DOCUMENT					TRANS	LATION	
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	WO 00/3908	06/07/00	WIPO					
	WO 94/1442	5 07/07/94	WIPO					
	WO 98/0452	05/02/98	WIPO					
	WO 98/2195	7 28/05/98	WIPO					
	отн	ER DOCUMENTS (Includi	ng Author, Titie, Date, Pertine	nt Pages, Etc				
	C.L. Bra	nd et al., "Imm	unoneutralization	of endo	genous glu	cagons	with	
	Monoclon	al glucagons ant	ibody normalizes	hypergl	ycaemia in	modera	tely	
I	Streptoz	otocin-diabetic	rats"Diabetologia	, Vol.	37 pgs.985	-993 (19	94)	
	C.L. Bra	nd et al [535] I	Diabetes 43, [supp	1], 1	72A (1994)			
	C.L. Bra	nd et al., Am J	. Physiol. 269, E4	169-E477	(1995)			
	C.L. Bra	nd et al [492] I	Diabetes 44 [supp]	1], 13	4A (1995)			
	1		dence for a Major			in Reg	u-	
	lation o	f Plasma Glucose	in Conscious, No	ondiabet	ic, and Al	loxan I	nduced	
			etes Vol. 45, pgs					
			xpression Cloning			perties	of	
	1 1		or" Science Vol. 2					
							·	
EXAMINER			DATE CONSIDERED					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

				Γ			Sh	eet 2 of 4	
FORM PTO-1449 (Rev. 2-32)			MENT OF COMMERCE TRADEMARK OFFICE	Atty. Docket No. 6202.210-US Serial No. To Be Assigned				1	
	INF STA	ORMATION DISCLOSURE		Applicant Behrens et al					
	(Use several sheets if necessary)				Filing Date September 9, 2003		assigned		
			U.S. PATE	ENT DOCUMENTS					
EXAMINER INITIAL	I	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	_								
	_		 		<u> </u>				
						L	L		
			FOREIGN P.	ATENT DOCUMENTS					
	-	DOCUMENT]		1		TRANS	LATION	
	\dashv	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	+	WO 98/22108	28/05/98	WIPO	ļ	<u> </u>			
	-+	WO 98/22109	28/05/98	WIPO	 				
		WO 99/01423	14/01/99	WIPO	├				
	-+	WO 97/16442	09/05/97	WIPO	├	ļ			
		WO 98/24780	11/06/98	WIPO	l	l	J	<u> </u>	
				ng Author, Title, Date, Pertin					
	1	C.G. Unson	C.G. Unson et al., "Biological Activities of des-His1 [Glu9]Glucagon						
				onist1"Peptides, to of action of des					
Ì		Petptide antagonist of the glucagons receptor system" Proc.Natl.Acad. Sci Vol. 90 pages 1662-1666 (1993)							
	\sqcup	Unson et al., "Multiple-site Replacement Analogs of Glucagon" The							
		Olison et a		- Site Replacement	Anurog				
	\vdash	Journal of	Journal of Biological Chemistry Vol. 17, Issue of April 29, pgs.						
			12548-12551(1994) J.L. Collins et al., "CP-99,711: A Non-Peptide Glucagon Receptor						
	Ш			Med.Chem. Ltr.				1021	
		Alltagonist		wed.chem. Ecr.	VO1.2, N				
	\vdash			···					
EXAMINER	لـــا			DATE CONSIDERED					

						I		neet 3 of		
FORM PTO-1449 (Rev. 2-32)			MENT OF COMMERCE TRADEMARK OFFICE	Aty, Docket No. 6202.210-US Sertal No. T Be Assigned Applicant Behrens et al						
	INFOR	RMATION DISCLOSURE EMENT BY APPLICANT								
	(Use several sheets if necessary)				Filing Date September 9, 2003			Group To be assigned		
			U.S. PATE	NT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
					+					
	_									
					<u> </u>	L				
			FOREIGN PA	ATENT DOCUMENTS	Т					
	DOCUMENT		DATE		CLASS		YES	NO NO		
	1	NUMBER WO 98/24782	11/06/98	WIPO	CLASS	SUBCLASS	163	1.00		
	$\neg \neg$	WO 99/24404	20/05/99	WIPO	-					
	WO 99/32448		01/07/99	WIPO						
		OTHER I	OCUMENTS (Includin	g Author, Title, Date, Perti	nent Pages, Et	:.)				
		Azizeh et al., "[des His¹, des Phe⁶, Glu³]Glucagon Amide: A newly								
		Designed "H	Pure" Glucagon	Antagonist", B	ioorganio	& Med.Che	m.Ltr,			
	<u> </u>	Vol. 5, No. 16 pages. 1849-1852 (1995)								
	P. Madsen et al., "Discovery and Structure-Activity Relationship of									
		The First Non-Peptide Competitive Human Glucagon Receptor Antagonists"								
		J. Med.Chem	n. Vol. 41, pa	ges 5150-5157 (1998)					
	-	-								
	-	+								
	\vdash	 								
EXAMINER				DATE CONSIDERED						

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

								Sh	ect 4 of	
FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				Atty. Docket No. 6202.210-US Serial No. To Be Assigned					
,	INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Applicant Behrens et al				
	(Use several sheets if necessary)				Filing Date September	Group To be assigned				
				U.S. PATE	INT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	T									
	\neg									
	\neg									
				PODETCH P.	ATTENTO DOCUMENTO					
			DOCUMENT	FOREIGN PA	ATENT DOCUMENTS	1		TRANS	LATION	
İ	DOCUMENT		(DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
		wc	00/69810	06/07/00	WIPO					
	$\neg \dagger$		00703010	00/01/00						
	_									
	\dashv									
	\dashv									
	\neg	_	OTHERI	OCUMENTS (Includin	g Author, Title, Date, Per	rtinent Pages, Et	:)			
Ì		-								
									-	
j										
EXAMINER					DATE CONSIDER	ED				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.